GlassScriptPhysician profile
Nitin N Mayur
NPI 1669462990
$3,065.57
in general payments reported to CMS, 2019-2025
36 companies · $651 in 2025
The $651 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $249 · 2021: $249 · 2022: $526 · 2023: $480 · 2024: $750 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,880.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $458.60 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $314.35 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $246.91 | 2019-2023 | |
| Amgen INC. | $236.50 | 2019-2025 | Tepezza, Evenity, Prolia |
| Lilly USA, LLC | $208.88 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Dexcom, INC. | $170.60 | 2022-2024 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $165.32 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Abbvie INC. | $112.69 | 2021-2024 | |
| Ibsa Pharma INC. | $104.72 | 2021-2025 | Tirosint, Tirosint, Licart |
| Cequr Corporation | $98.36 | 2022-2025 | Cequr Simplicity |
| Antares Pharma, INC. | $98.14 | 2019-2023 | Nocdurna, Xyosted, Tlando |
| Mannkind Corporation | $83.56 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $60.19 | 2021-2025 | Unithroid |
| Sequel Med Tech, LLC | $58.87 | 2025 | Twiist |
| Neurocrine Biosciences, INC. | $53.21 | 2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $52.59 | 2022-2025 | Gvoke Hypopen |
| Medtronic Minimed, INC. | $52.11 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $45.05 | 2020-2021 | |
| Amphastar Pharmaceuticals, INC. | $44.60 | 2024 | |
| Horizon Therapeutics Plc | $41.03 | 2023 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $36.37 | 2022 | |
| Ascendis Pharma Endocrinology INC | $35.40 | 2024-2025 | Yorvipath |
| Amryt Pharma Holdings LTD | $34.84 | 2022 | |
| Amarin Pharma, INC. | $34.33 | 2021 | |
| Insulet Corporation | $30.71 | 2019-2020 | |
| Zealand Pharma US, INC. | $25.58 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $24.95 | 2022 | |
| Tandem Diabetes Care, INC. | $19.87 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascensia Diabetes Care US INC. | $18.74 | 2025 | |
| Pfizer INC. | $15.53 | 2022 | |
| Radius Health, INC. | $15.51 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.24 | 2024 | Jardiance |
| Medtronic, INC. | $14.54 | 2024 | Minimed 780g |
| Shire North American Group INC | $13.32 | 2019 | |
| Esperion Therapeutics, INC. | $12.85 | 2020 | |
| Becton, Dickinson and Company | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Mayur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.